Goldman Sachs analyst David Roman initiates coverage on $Tandem Diabetes Care (TNDM.US)$ with a hold rating, and sets the target price at $46.
According to TipRanks data, the analyst has a success rate of 68.0% and a total average return of 4.7% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Tandem Diabetes Care (TNDM.US)$'s main analysts recently are as follows:
The outlook for insulin pump adoption within the Type 1 diabetes demographic is positive, which is expected to support further market share gains for Tandem Diabetes, bolstered by forthcoming product cycles. Nevertheless, current projections seem to already reflect this optimistic growth trajectory, with additional upside potentially hinging on increased Type 2 diabetes adoption, more significant market share advancements, or a hastened path to profitability.
The significant upside potential for Tandem Diabetes is anticipated due to earnings revisions and multiple expansion. The expected earnings increase is likely to stem from the adoption of Mobi, integration with continuous glucose monitoring systems, and the expansion of Type 2 indications, which could contribute to acquiring new patients and pump renewals. Despite the presence of weight loss drugs, Tandem's global pump market opportunity remains largely untapped.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
高盛集团分析师David Roman首予$Tandem Diabetes Care (TNDM.US)$持有评级，目标价46美元。
根据TipRanks数据显示，该分析师近一年总胜率为68.0%，总平均回报率为4.7%。
此外，综合报道，$Tandem Diabetes Care (TNDM.US)$近期主要分析师观点如下：
在即将到来的产品周期的推动下，1型糖尿病人群采用胰岛素泵的前景乐观，预计这将支持串联糖尿病市场份额的进一步增长。尽管如此，目前的预测似乎已经反映了这种乐观的增长轨迹，额外的上行空间可能取决于2型糖尿病采用率的增加、更显著的市场份额增长或盈利之路的加快。
由于收益调整和多次扩张，预计 Tandem Diabetes 具有巨大的上行潜力。预期的收益增长可能源于Mobi的采用、与持续血糖监测系统的整合以及2型适应症的扩大，这可能有助于吸引新患者和续订新药物。尽管存在减肥药物，但Tandem的全球泵市场机会仍基本上未被利用。
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
